Antialbuminuric actions of calcilytics in the remnant kidney

Tsuneo Takenaka, Tsutomu Inoue, Takashi Miyazaki, Akira Nishiyama, Naohito Ishii, Matsuhiko Hayashi, Hiromichi Suzuki

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Hyperphosphatemia accelerates the progression of chronic kidney diseases. In the present study, the effects of ronacaleret, a calcilytic agent, on renal injury were assessed in the following four groups of rats: 5/6-nephrectomized Wistar rats as a control (C group), rats treated with ronacaleret (3 mg·kg<sup>-1</sup>·day<sup>-1</sup>; R group), rats treated with calcitriol (30 ng·kg<sup>-1</sup>·day<sup>-1</sup>; V group), and rats treated with both ronacaleret and calcitriol (R + V group). Three months later, rats were euthanized under anesthesia, and the remnant kidneys were harvested for analysis. Albuminuria was lower in the R and V groups than in the C group (P < 0.05). Creatinine clearance was elevated in the R and V groups compared with the C group (P < 0.05). Serum Ca<sup>2+</sup> and renal ANG II were higher in the R + V group than in the C group (P < 0.05 for each), and serum phosphate was reduced in the R group compared with the C group (P < 0.05). Fibroblast growth factor-23 was lower in the R group and higher in the V and R + V groups than in the C group. However, parathyroid hormone did not differ significantly among the four groups. Renal klotho expression was elevated in the R and V groups compared with the C group (P < 0.05). The present data indicate that ronacaleret preserves klotho expression and renal function with reductions in serum phosphate and albuminuria in 5/6-nephrectomized rats. Our findings demonstrate that vitamin D prevents declines in klotho expression and renal function, suppressing albuminuria.

Original languageEnglish
Pages (from-to)F216-F226
JournalAmerican Journal of Physiology - Renal Physiology
Volume309
Issue number3
DOIs
Publication statusPublished - 2015 Aug 5

Fingerprint

Kidney
Albuminuria
Calcitriol
Renal Agents
Phosphates
Hyperphosphatemia
Parathyroid Hormone
Serum
Chronic Renal Insufficiency
Vitamin D
Wistar Rats
Anesthesia
Control Groups
ronacaleret
Wounds and Injuries

Keywords

  • Calcium-sensing receptor
  • Klotho
  • Phosphate
  • Transient receptor potential channel 6
  • Vitamin D

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Takenaka, T., Inoue, T., Miyazaki, T., Nishiyama, A., Ishii, N., Hayashi, M., & Suzuki, H. (2015). Antialbuminuric actions of calcilytics in the remnant kidney. American Journal of Physiology - Renal Physiology, 309(3), F216-F226. https://doi.org/10.1152/ajprenal.00003.2015

Antialbuminuric actions of calcilytics in the remnant kidney. / Takenaka, Tsuneo; Inoue, Tsutomu; Miyazaki, Takashi; Nishiyama, Akira; Ishii, Naohito; Hayashi, Matsuhiko; Suzuki, Hiromichi.

In: American Journal of Physiology - Renal Physiology, Vol. 309, No. 3, 05.08.2015, p. F216-F226.

Research output: Contribution to journalArticle

Takenaka, T, Inoue, T, Miyazaki, T, Nishiyama, A, Ishii, N, Hayashi, M & Suzuki, H 2015, 'Antialbuminuric actions of calcilytics in the remnant kidney', American Journal of Physiology - Renal Physiology, vol. 309, no. 3, pp. F216-F226. https://doi.org/10.1152/ajprenal.00003.2015
Takenaka T, Inoue T, Miyazaki T, Nishiyama A, Ishii N, Hayashi M et al. Antialbuminuric actions of calcilytics in the remnant kidney. American Journal of Physiology - Renal Physiology. 2015 Aug 5;309(3):F216-F226. https://doi.org/10.1152/ajprenal.00003.2015
Takenaka, Tsuneo ; Inoue, Tsutomu ; Miyazaki, Takashi ; Nishiyama, Akira ; Ishii, Naohito ; Hayashi, Matsuhiko ; Suzuki, Hiromichi. / Antialbuminuric actions of calcilytics in the remnant kidney. In: American Journal of Physiology - Renal Physiology. 2015 ; Vol. 309, No. 3. pp. F216-F226.
@article{8253947f984344fdbf99031f43853993,
title = "Antialbuminuric actions of calcilytics in the remnant kidney",
abstract = "Hyperphosphatemia accelerates the progression of chronic kidney diseases. In the present study, the effects of ronacaleret, a calcilytic agent, on renal injury were assessed in the following four groups of rats: 5/6-nephrectomized Wistar rats as a control (C group), rats treated with ronacaleret (3 mg·kg-1·day-1; R group), rats treated with calcitriol (30 ng·kg-1·day-1; V group), and rats treated with both ronacaleret and calcitriol (R + V group). Three months later, rats were euthanized under anesthesia, and the remnant kidneys were harvested for analysis. Albuminuria was lower in the R and V groups than in the C group (P < 0.05). Creatinine clearance was elevated in the R and V groups compared with the C group (P < 0.05). Serum Ca2+ and renal ANG II were higher in the R + V group than in the C group (P < 0.05 for each), and serum phosphate was reduced in the R group compared with the C group (P < 0.05). Fibroblast growth factor-23 was lower in the R group and higher in the V and R + V groups than in the C group. However, parathyroid hormone did not differ significantly among the four groups. Renal klotho expression was elevated in the R and V groups compared with the C group (P < 0.05). The present data indicate that ronacaleret preserves klotho expression and renal function with reductions in serum phosphate and albuminuria in 5/6-nephrectomized rats. Our findings demonstrate that vitamin D prevents declines in klotho expression and renal function, suppressing albuminuria.",
keywords = "Calcium-sensing receptor, Klotho, Phosphate, Transient receptor potential channel 6, Vitamin D",
author = "Tsuneo Takenaka and Tsutomu Inoue and Takashi Miyazaki and Akira Nishiyama and Naohito Ishii and Matsuhiko Hayashi and Hiromichi Suzuki",
year = "2015",
month = "8",
day = "5",
doi = "10.1152/ajprenal.00003.2015",
language = "English",
volume = "309",
pages = "F216--F226",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Antialbuminuric actions of calcilytics in the remnant kidney

AU - Takenaka, Tsuneo

AU - Inoue, Tsutomu

AU - Miyazaki, Takashi

AU - Nishiyama, Akira

AU - Ishii, Naohito

AU - Hayashi, Matsuhiko

AU - Suzuki, Hiromichi

PY - 2015/8/5

Y1 - 2015/8/5

N2 - Hyperphosphatemia accelerates the progression of chronic kidney diseases. In the present study, the effects of ronacaleret, a calcilytic agent, on renal injury were assessed in the following four groups of rats: 5/6-nephrectomized Wistar rats as a control (C group), rats treated with ronacaleret (3 mg·kg-1·day-1; R group), rats treated with calcitriol (30 ng·kg-1·day-1; V group), and rats treated with both ronacaleret and calcitriol (R + V group). Three months later, rats were euthanized under anesthesia, and the remnant kidneys were harvested for analysis. Albuminuria was lower in the R and V groups than in the C group (P < 0.05). Creatinine clearance was elevated in the R and V groups compared with the C group (P < 0.05). Serum Ca2+ and renal ANG II were higher in the R + V group than in the C group (P < 0.05 for each), and serum phosphate was reduced in the R group compared with the C group (P < 0.05). Fibroblast growth factor-23 was lower in the R group and higher in the V and R + V groups than in the C group. However, parathyroid hormone did not differ significantly among the four groups. Renal klotho expression was elevated in the R and V groups compared with the C group (P < 0.05). The present data indicate that ronacaleret preserves klotho expression and renal function with reductions in serum phosphate and albuminuria in 5/6-nephrectomized rats. Our findings demonstrate that vitamin D prevents declines in klotho expression and renal function, suppressing albuminuria.

AB - Hyperphosphatemia accelerates the progression of chronic kidney diseases. In the present study, the effects of ronacaleret, a calcilytic agent, on renal injury were assessed in the following four groups of rats: 5/6-nephrectomized Wistar rats as a control (C group), rats treated with ronacaleret (3 mg·kg-1·day-1; R group), rats treated with calcitriol (30 ng·kg-1·day-1; V group), and rats treated with both ronacaleret and calcitriol (R + V group). Three months later, rats were euthanized under anesthesia, and the remnant kidneys were harvested for analysis. Albuminuria was lower in the R and V groups than in the C group (P < 0.05). Creatinine clearance was elevated in the R and V groups compared with the C group (P < 0.05). Serum Ca2+ and renal ANG II were higher in the R + V group than in the C group (P < 0.05 for each), and serum phosphate was reduced in the R group compared with the C group (P < 0.05). Fibroblast growth factor-23 was lower in the R group and higher in the V and R + V groups than in the C group. However, parathyroid hormone did not differ significantly among the four groups. Renal klotho expression was elevated in the R and V groups compared with the C group (P < 0.05). The present data indicate that ronacaleret preserves klotho expression and renal function with reductions in serum phosphate and albuminuria in 5/6-nephrectomized rats. Our findings demonstrate that vitamin D prevents declines in klotho expression and renal function, suppressing albuminuria.

KW - Calcium-sensing receptor

KW - Klotho

KW - Phosphate

KW - Transient receptor potential channel 6

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84938571665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938571665&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00003.2015

DO - 10.1152/ajprenal.00003.2015

M3 - Article

C2 - 26017971

AN - SCOPUS:84938571665

VL - 309

SP - F216-F226

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 3

ER -